Breaking News Headlines Today | Ground News

See every side of every news story

endpoints.news image

News from endpoints.news

endpoints.news’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

endpoints.news’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about endpoints.news

Where is endpoints.news located?endpoints.news's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top endpoints.news News

Trump signs funding bill into law, ending record-long government shutdown — Win McNamee/Getty Images via Getty Images

Government Shutdown · United States

Trump signs funding bill into law, ending record-long government shutdown

51% Center coverage: 582 sources

President Donald Trump on Wednesday night signed into law legislation that reopens the federal government and ends an acrimonious 43-day shutdown, the longest in American history.See the Story

Pfizer completes up to $10 billion acquisition of Metsera — REUTERS / pwu404

Pfizer · United States

Pfizer completes up to $10 billion acquisition of Metsera

55% Center coverage: 20 sources

Pfizer on Thursday closed its up to $10 billion acquisition of Metsera after winning shareholder approval, gaining a foothold in the fast-growing obesity market following a fierce bidding war with Novo Nordisk.See the Story

Merck bets on flu prevention with $9.2 billion deal for Cidara Therapeutics — REUTERS / pwu404

Merck · United States

Merck bets on flu prevention with $9.2 billion deal for Cidara Therapeutics

67% Center coverage: 12 sources

Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an experimental drug for flu prevention.Merck is looking to diversify its revenue beyond Keytruda as its patents for the blockbuster drug begin to expire later this decade.See the Story

Breaking News Topics Related to endpoints.news